Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?

F1000Research
Sajan KhoslaSandra Leonard

Abstract

Stakeholders in healthcare are increasingly turning to real world evidence (RWE) to inform their decisions, alongside evidence from randomized controlled trials. RWE is generated by analysing data gathered from routine clinical practice, and can be used across the product lifecycle, providing insights into areas including disease epidemiology, treatment effectiveness and safety, and health economic value and impact. Recently, the US Food and Drug Administration and the European Medicines Agency have stated their ambition for greater use of RWE to support applications for new indications, and are now consulting with their stakeholders to formalize standards and expected methods for generating RWE. Pharmaceutical companies are responding to the increasing demands for RWE by developing standards and processes for each stage of the evidence generation pathway. Some conventions are already in place for assuring quality, whereas other processes are specific to the research question and data sources available. As evidence generation increasingly becomes a core role of medical affairs divisions in large pharmaceutical companies, standards of rigour will continue to evolve and improve. Senior pharmaceutical leaders can drive this change...Continue Reading

References

Feb 6, 2008·Proceedings of the National Academy of Sciences of the United States of America·Francesco FornaiAntonio Paparelli
Jul 2, 2011·Nature Reviews. Drug Discovery·Hans-Georg EichlerBrigitte Bloechl-Daum
Mar 22, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Marc L BergerSharon-Lise Normand
Jan 1, 2012·Journal of Comparative Effectiveness Research·Robert S EpsteinTehseen Salimi
Mar 13, 2014·Journal of Clinical Epidemiology·Amand F SchmidtRieke van der Graaf
Dec 3, 2014·BMJ : British Medical Journal·Karin E JohnsonEric B Larson
Jan 18, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Marc L BergerDavid Madigan
May 7, 2015·Journal of Managed Care & Specialty Pharmacy·Eleanor M PerfettoMena Gaballah
May 10, 2015·BMJ : British Medical Journal·Kirsty LoudonMerrick Zwarenstein
Oct 7, 2015·PLoS Medicine·Eric I BenchimolUNKNOWN RECORD Working Committee
Nov 10, 2015·Journal of Clinical Epidemiology·Sally C MortonRobert W Dubois
Mar 16, 2016·Scientific Data·Mark D WilkinsonBarend Mons
Sep 7, 2016·The New England Journal of Medicine·Jørgen VestboUNKNOWN Salford Lung Study Investigators
Oct 21, 2016·Journal of Comparative Effectiveness Research·Richard White
Nov 16, 2016·Perspectives in Clinical Research·Amit Dang, B N Vallish
Apr 15, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Amr MakadyUNKNOWN GetReal Workpackage 1
Jul 13, 2017·Journal of Comparative Effectiveness Research·Sarah Wamala Andersson, Mattias Kyhlstedt
Oct 2, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Marc L BergerC Daniel Mullins
Oct 2, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Shirley V WangUNKNOWN joint ISPE‐ISPOR Special Task Force on Real World Evidence in Health Care Decision Making
Oct 6, 2017·Neurology·Ruben P A van EijkUNKNOWN For UKMND-LiCALS and LITALS Study Group

❮ Previous
Next ❯

Citations

Mar 8, 2019·Journal of Diabetes Science and Technology·David C Klonoff
Sep 5, 2018·Clinical Pharmacology and Therapeutics·Hans-Georg EichlerValerie Paris
Jun 22, 2019·JCO Clinical Cancer Informatics·Marjorie G ZaudererMark G Kris
May 13, 2019·Archives of Disease in Childhood. Fetal and Neonatal Edition·Jacqueline van DrutenHassan Abdalla
Apr 25, 2020·JMIR Medical Education·William MagagnaKyle Peck
Apr 7, 2020·Diabetes, Obesity & Metabolism·John D SeegerAnita M Loughlin
May 7, 2020·Journal of the American Medical Informatics Association : JAMIA·Madison Milne-IvesEdward Meinert
Sep 10, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Xuejun Victor PengLawrence Blonde
Sep 24, 2020·Pharmacology Research & Perspectives·Juan-Sebastian Franco, David Vizcaya
Sep 12, 2018·Journal of Wound Care·Ruth ScullyPhilip Bowler
Nov 20, 2019·Drugs -- Real World Outcomes·Andrew D XiaMatthew J Hirst
Jul 8, 2020·Therapeutic Innovation & Regulatory Science·Robert J LoCasaleSajan Khosla
Jun 7, 2019·Diabetes Technology & Therapeutics·Fredrick DebongJohanna Kober
Jun 20, 2020·Expert Opinion on Drug Safety·Diana CrestanPaolo Baldo
Jun 20, 2020·PharmacoEconomics Open·Melissa H Roberts, Gary T Ferguson
Dec 12, 2019·Pharmacoepidemiology and Drug Safety·Elodie Baumfeld AndreNancy A Dreyer
Jun 19, 2019·BMC Endocrine Disorders·Guntram SchernthanerHarald Sourij
Jun 7, 2019·Diabetes Technology & Therapeutics·Joseph A Cafazzo
Feb 19, 2021·BMC Medical Informatics and Decision Making·Wade L SchulzHarlan M Krumholz
Aug 1, 2020·Journal of the American College of Cardiology·Alexander C FanaroffRenato D Lopes
May 29, 2021·Future Oncology·Fernando PetracciMarwan Ghosn
Sep 22, 2021·Diabetes Technology & Therapeutics·Timothy S Bailey, Shridhara Alva
Dec 29, 2020·Endocrinología, Diabetes Y Nutrición·Nicolás Coronel-RestrepoJosé Fernando Botero
Oct 17, 2021·Clinical Pharmacology and Therapeutics·Douglas McNairDaniel Hartman
Feb 9, 2021·Clinical Diabetes : a Publication of the American Diabetes Association·Clifford J Bailey, James R Gavin

❮ Previous
Next ❯

Software Mentioned

GetReal RWE Navigator
GetReal
PatientsLikeMe

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.